Posts tagged “Pozen”
Pozen strikes manufacturing pact with Patheon for heart drug
Pozen's new cardiovascular drug does not even have a name yet, but it has a manufacturer to produce it once it gets U.S. Food and Drug Administration approval.
Pozen's $75M deal - It's all about cash for product pipeline
The money strengthens Pozen's negotiating position as it seeks a partner for a drug under development and does so without diluting Pozen's shareholders, CEO John Platchetka
Pozen sells royalty rights to migraine drug for $75M
Treximet is marketed in the United States by Pozen drug partner GlaxoSmithKline. The royalty rights were purchased by a Canadian pension plan.
Pozen CEO criticizes partner AstraZeneca for slow drug sales
"Although last quarter's U.S. net sales were up from the second quarter, the $13.4 million year to date total is well below what we think Vimovo is capable of selling so AstraZeneca has work to be done to make that better," John Platchetka says.
Tech earnings: Pozen, DexOne, Biocryst, Furiex, Targacept
It's been a busy earnings week, and five North Carolina firms all reported losses.
Losers in Treximet patent decision are appealing
A securities filing by patent-holder Pozen says that generic drug-makers are appealing a ruling by a judge in that Pozen had exclusive rights to Treximet.
Pozen names exec for customer development
The Chapel Hill-based pharmaceutical firm looks to boost its own pipeline of products.
What a relief - Pozen prevails in patent fight
Pozen had sued the Par, Alphapharm and Dr. Reddy's claiming that those generic product infringe on its three migraine drug patents. The litigation was consolidated into one suit that was tried last October.
Pozen forms advisory board for thoughts on digital development
The Chapel Hill-based pharmaceutical firm is seeking advice about how to revolutionize drug industry marketing and development.
Pozen secures preliminary injunction against generic producer
The court order bars Par Pharmaceutical from producing a version of Pozen's Treximet, which is sold by GlaxoSmithKline.
$25M milestone payment lifts Pozen to profitability
The Chapel Hill-based drug development firm reports a positive fourth quarter and full year financials.
